Pharma Spends 0.3% Of Sales On Post-Market Safety Activities, CERT Says
Executive Summary
Pharmaceutical companies spend an average 0.3% of sales on post-marketing safety studies, an unpublished Centers for Education & Research on Therapeutics report finds
You may also be interested in...
Drugs With Better Sales Have Better Development Times, Study Finds
Drugs with strong sales were developed more quickly than drugs with weaker sales, according to an analysis published in the March/April issue of Health Affairs
Drugs With Better Sales Have Better Development Times, Study Finds
Drugs with strong sales were developed more quickly than drugs with weaker sales, according to an analysis published in the March/April issue of Health Affairs
IoM Drug Safety Review Should Reach Beyond FDA, Agency’s Woodcock Says
The scope of the Institute of Medicine's assessment of the U.S. drug safety system must extend beyond an evaluation of FDA's capabilities, FDA Acting Deputy Commissioner for Operations Janet Woodcock said June 8